Engineers at Duke University recently unveiled a new technology called SonoPIN that helps large cancer drugs enter tumor cells. The method uses microbubbles and ultrasound waves to precisely deliver medications, causing 50% of targeted cancer cells to self-destruct in lab tests. This breakthrough could make cancer treatments more effective by overcoming a major challenge with drug delivery.[news-medical+2]
New Way to Get Drugs Inside Cancer Cells
Many promising cancer drugs, especially larger molecules like proteolysis-targeting chimeras (PROTACs), struggle to get inside cells. Their size makes it hard for them to cross the protective cell membrane. This often leads to drugs not working well or causing side effects by affecting healthy cells.[news-medical+1]
SonoPIN, short for Sonoporation-assisted Precise Intracellular Nanodelivery, solves this problem. It allows these large drugs to enter targeted cancer cells while largely ignoring healthy ones.This precision is key to improving cancer therapy.[news-medical+2]
How SonoPIN Works
The SonoPIN technology uses specially designed microbubbles. These microbubbles are engineered to attach only to cancer cells. They do this by using synthetic nucleic acid strands that recognize unique markers found on cancer cell membranes.[bioengineer+1]
Once attached, controlled ultrasound waves are directed at these microbubbles. The ultrasound makes the microbubbles collapse rapidly. This violent collapse creates mechanical forces, including high-velocity microjets and shock waves, that are aimed at the nearby cancer cells.[news-medical+1]
These forces create tiny, temporary pores in the cancer cell membrane. These nanoscale openings are just big enough for large drugs like PROTACs to pass through and get inside the cell. Importantly, these pores close up naturally within minutes, minimizing long-term damage to the cell.[news-medical+1]
Yuqi Wu, a doctoral student in mechanical engineering and materials science at Duke, explained the challenge. "PROTAC molecules are too big to get into cells in the first place," Wu said. "But with our SonoPIN platform, the PROTACs can enter into targeted cancer cells while almost completely ignoring non-targeted cells."[news-medical+1]
Impressive Lab Results
In benchtop experiments, the SonoPIN platform showed remarkable effectiveness. Researchers found that half of the targeted cancer cells self-destructed. At the same time, 99% of the non-targeted healthy cells remained unharmed.This level of precision is a significant advancement.[news-medical+3]
The team also measured how much drug entered the cells. Cells treated with SonoPIN glowed seven times brighter than those treated with older PROTAC delivery methods. This indicated a much higher amount of PROTACs accumulating inside the cells.This increased uptake means the drugs can work more effectively.[news-medical+2]
Targeting "Undruggable" Proteins
The research focused on PROTACs, a new class of drugs. PROTACs work by binding to a specific target protein in cancer cells and then recruiting an enzyme. This enzyme marks the target protein for destruction by the body's natural waste system.[news-medical+1]
In these experiments, PROTACs were used to target a protein called BRD4. When BRD4 is destroyed, cancer cells lose their ability to reproduce quickly and survive. This effectively forces them to self-destruct.A major problem with BRD4 is that it is also essential for healthy cells. SonoPIN's precise delivery helps avoid harming these healthy cells.[news-medical+4]
Tony Jun Huang, a distinguished professor at Duke, highlighted the versatility of SonoPIN. "And because SonoPIN relies on a mechanical delivery approach rather than biological engulfment, it could theoretically deliver therapeutics of almost any size," Huang said.He also expressed excitement about its potential with large gene-editing complexes.[news-medical+2]
Future Steps and Potential Impact
The Duke University team published their findings on March 13 in the journal Proceedings of the National Academy of Sciences.The researchers have already applied for a patent for the SonoPIN technology.[news-medical+1]
Moving forward, the next step is to test this approach in mouse models.The scientists believe that by injecting PROTACs and the cancer-seeking microbubbles into the bloodstream and focusing ultrasound waves on tumor locations, SonoPIN could become a highly potent cancer-killing technology with minimal side effects.[news-medical+2]
This innovation represents a significant step toward more precise and effective cancer treatments. By enabling large, powerful drugs to reach their targets within cancer cells, SonoPIN offers new hope for patients and researchers in the fight against various cancers.[bioengineer+1]
